New GLP-1 RA ‘better than semaglutide’ for weight loss in Lancet study
A high dose of a new once-weekly injected GLP-1 receptor agonist has outdone semaglutide for weight loss in a phase III trial. Ecnoglutide, developed in…
Tag: GLP-1 RA
Daily pill looming for GLP-1 receptor agonists? Eli Lilly drafting TGA application
Eli Lilly is preparing a TGA application for an oral GLP-1 receptor agonist to treat early diabetes following publication of phase III trial results. The…
Tirzepatide approved to treat sleep apnoea in patients with obesity
Tirzepatide is now TGA registered to treat moderate to severe obstructive sleep apnoea in patients with obesity. Drug maker Eli Lilly says tirzepatide (Mounjaro) is the…
The dismal science returns: How do you make GLP-1 RAs worth taxpayers’ money?
There are many wondrous things about GLP-1 receptor agonists, not least their capacity to cripple health budgets. Given the scale of obesity and its economic…
Tirzepatide reduces weight more than semaglutide in head-to-head trial of patients without diabetes
Tirzepatide leads to greater weight loss than semaglutide in adults with obesity but without type 2 diabetes, a head-to-head trial suggests. Published in the New…
Semaglutide associated with vision loss in large observational study
A retrospective cohort study has linked semaglutide to double the risk of serious optic neuropathy in type 2 diabetes patients. Published in JAMA Ophthalmology, the…
‘They are devastated’: When your patient discovers stopping semaglutide means the weight returns
Semaglutide is a game changer for patients right up until they stop the treatment, when many face the heartbreak of watching the kilos return. That…
TGA approves Wegovy for reducing MACE risk
The TGA has approved Wegovy to reduce the risk of major adverse events in patients with cardiovascular disease who are overweight or obese. The once-weekly…
GLP-1 RAs linked to eye complications in JAMA case series
A case series has rekindled concerns about potential eye-related complications associated with semaglutide and tirzepatide. Published in JAMA Ophthalmology, it documents instances of serious ophthalmic…
An eye-opener? GLP-1 RAs linked to reduced risk of 42 conditions from dementia to infections
A major study of nearly two million patients with type 2 diabetes has highlighted the potential wide-ranging health benefits of GLP-1 receptor agonists — but…
